Ontology highlight
ABSTRACT: Background
Central sleep apnea (CSA) is a breathing disorder caused by the intermittent absence of central respiratory drive. Transvenous phrenic nerve stimulation is a new therapeutic option, recently approved by the FDA , for the treatment of CSA.Objective
To describe the technique used to implant the transvenous phrenic nerve stimulation system (the remedē System, Respicardia, Inc).Methods
The remedē System is placed in the pectoral region, typically on the right side. A single stimulation lead is placed in either the left pericardiophrenic vein (PPV) or the right brachiocephalic vein (RBC). A sensing lead is placed into the azygous vein to detect respiration.Results
In the remedē System Pivotal trial, 147 of 151 (97%) patients were successfully implanted
SUBMITTER: Augostini RS
PROVIDER: S-EPMC6850096 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature